Diagnosing AMD as early as possible permits interventional management prior to the onset of any major structural or functional damage. A major goal of disease management is the identification of pre-symptomatic patients using a robust, reproducible and clinically relevant marker for the disease and/or progression of disease. In addition, clinical trials for new experimental AMD treatments may benefit from non-invasive outpatient procedures capable of assessing the impact of a drug on disease progression. Recent clinical data using a combination of 14-Hz flicker assessment and dynamics of the photo-stress recovery (PSR) appear to show that 71% of abnormal AMD cases could be detected using simple standardized and already established methodologies.